Eli Lilly to acquire private equity-backed drugmaker for up to $1.9B
Versanis, founded in 2021 by a venture capital firm, is primarily known as the company behind the obesity drug bimagrumab.
Related Articles
Apple Watch AFib feature becomes first-ever digital tool approved by FDA to evaluate medical devices
Healthcare technology companies can now use AFib findings recorded by an Apple Watch to help demonstrate the effectiveness of their devices to the FDA.
Cardiologists and surgeons perform world’s first robot-assisted TEER
A 62-year-old women presented with severe MR and recurrent heart failure episodes. Initial data suggest the procedure was a success.
Private equity-backed cardiology group acquires Arizona practice with 4 locations
Florida-based Cardiovascular Associates of America has expanded its roster to include a team of 14 cardiologists and advanced practitioners in Arizona.
ChatGPT struggles to evaluate heart risk—but it could still help cardiologists
Relying on the AI-powered chatbot for heart assessments could be “dangerous,” researchers warn, but the technology may still be helpful in certain situations.
ChatGPT struggles to evaluate heart risk—but it could still help cardiologists
Relying on the AI-powered chatbot for heart assessments could be “dangerous,” researchers warn, but the technology may still be helpful in certain situations.
Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways
Interventional cardiologists explored STS/ACR data from nearly 30,000 TAVR patients, presenting their findings in the Journal of the American Heart Association.
PAD patients face greater risk of death, complications after a heart attack
PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million…
ChatGPT struggles to evaluate heart risk—but it could still help cardiologists
Relying on the AI-powered chatbot for heart assessments could be “dangerous,” researchers warn, but the technology may still be helpful in certain situations.
Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways
Interventional cardiologists explored STS/ACR data from nearly 30,000 TAVR patients, presenting their findings in the Journal of the American Heart Association.
SCAI 2024 Scientific Sessions to focus on TAVR, PAD and other key trends in interventional cardiology
Interventional cardiologists from all over the world will gather for three days of educational sessions, late-breaking presentations, live cases and more. The festivities begin Thursday,…